Circulating microaggregates as biomarkers for the Post-COVID syndrome.
Hermann, M, Lisch, C, Gerth, R et al. · IDCases · 2024 · DOI
Quick Summary
This study describes one patient with long COVID who experienced severe fatigue, worsening after exertion, pain, and neurological symptoms. Researchers used a special microscopy technique to examine the patient's blood and found tiny clumps of blood cells and proteins (microaggregates) that shouldn't normally be there. After the patient received blood-thinning medications and antiviral treatment, these clumps dissolved and their symptoms significantly improved.
Why It Matters
This study identifies a potential blood-based biomarker (microaggregates) that could help diagnose and monitor post-COVID syndrome and potentially ME/CFS, conditions that currently lack objective biological markers. The observation that anticoagulant therapy improved symptoms provides a testable hypothesis for a pathophysiological mechanism and potential treatment avenue worth investigating in larger populations.
Observed Findings
Presence of circulating microaggregates (platelet, leukocyte, and plasma protein aggregates) in peripheral blood of post-COVID patient
Specific cellular immune reactivity to Epstein-Barr virus
Dissolution of microaggregates following anticoagulatory and antiviral pharmacological therapy
Stable clinical remission of fatigue, post-exertional malaise, pain, and neurological symptoms after treatment
Inferred Conclusions
Circulating microaggregates may be a morphological indicator of chronic post-COVID syndrome
Procoagulant state and dormant viral reactivation may contribute to post-COVID pathophysiology
Anticoagulatory and virustatic therapy may be therapeutic targets in post-COVID syndrome
Remaining Questions
Are microaggregates present in other post-COVID patients and ME/CFS patients, and how specific are they to these conditions?
Does the presence of microaggregates correlate with symptom severity, and can they serve as a reliable diagnostic or prognostic biomarker?
Will anticoagulant and antiviral therapy benefit other patients with post-COVID or ME/CFS, and what are the safety considerations for long-term use?
What This Study Does Not Prove
This single case report cannot prove that microaggregates cause post-COVID symptoms or that anticoagulant therapy will help other patients. The clinical improvement could be coincidental or attributable to other factors. No control group or comparison populations were studied, so it remains unclear whether microaggregates are specific to post-COVID or present in other conditions.